ZA202401922B - Coronavirus vaccine formulations - Google Patents

Coronavirus vaccine formulations

Info

Publication number
ZA202401922B
ZA202401922B ZA2024/01922A ZA202401922A ZA202401922B ZA 202401922 B ZA202401922 B ZA 202401922B ZA 2024/01922 A ZA2024/01922 A ZA 2024/01922A ZA 202401922 A ZA202401922 A ZA 202401922A ZA 202401922 B ZA202401922 B ZA 202401922B
Authority
ZA
South Africa
Prior art keywords
nanoparticles
vaccine formulations
coronavirus vaccine
vaccines
disclosed
Prior art date
Application number
ZA2024/01922A
Other languages
English (en)
Inventor
Gale Smith
Michael J Massare
Jing-Hui Tian
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/997,001 external-priority patent/US10953089B1/en
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of ZA202401922B publication Critical patent/ZA202401922B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
ZA2024/01922A 2020-01-27 2024-03-07 Coronavirus vaccine formulations ZA202401922B (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US202062966271P 2020-01-27 2020-01-27
US202062976858P 2020-02-14 2020-02-14
US202062983180P 2020-02-28 2020-02-28
US202063048945P 2020-07-07 2020-07-07
US202063051706P 2020-07-14 2020-07-14
US202063054182P 2020-07-20 2020-07-20
US16/997,001 US10953089B1 (en) 2020-01-27 2020-08-19 Coronavirus vaccine formulations
US202063129392P 2020-12-22 2020-12-22

Publications (1)

Publication Number Publication Date
ZA202401922B true ZA202401922B (en) 2025-04-30

Family

ID=77079351

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/01922A ZA202401922B (en) 2020-01-27 2024-03-07 Coronavirus vaccine formulations

Country Status (13)

Country Link
US (1) US12691171B2 (enExample)
EP (1) EP4097123A4 (enExample)
JP (2) JP7792339B2 (enExample)
CN (1) CN115720581A (enExample)
AU (1) AU2021214064A1 (enExample)
BR (1) BR112022014830A2 (enExample)
CA (1) CA3165371A1 (enExample)
GB (1) GB2610070A (enExample)
IL (1) IL295142A (enExample)
MX (1) MX2022009167A (enExample)
TW (1) TW202142555A (enExample)
WO (1) WO2021154812A1 (enExample)
ZA (1) ZA202401922B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021214064A1 (en) 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
CN118490818A (zh) 2020-04-22 2024-08-16 生物技术欧洲股份公司 冠状病毒疫苗
WO2021249116A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Coronavirus vaccine compositions, methods, and uses thereof
WO2021249011A1 (en) 2020-06-10 2021-12-16 Sichuan Clover Biopharmaceuticals, Inc. Hiv vaccine compositions, methods, and uses thereof
WO2022041760A1 (en) 2020-08-31 2022-03-03 Sichuan Clover Biopharmaceuticals, Inc. Methods and compositions for purification of trimeric fusion proteins
JP2024516309A (ja) * 2021-05-05 2024-04-12 ノババックス，インコーポレイテッド コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法
CN113773372B (zh) * 2021-08-15 2024-08-02 北京科兴中维生物技术有限公司 重组蛋白及其制备方法和应用
WO2023025287A1 (zh) * 2021-08-26 2023-03-02 江苏瑞科生物技术股份有限公司 新型冠状病毒免疫原性物质、其制备方法和应用
CN116808189A (zh) * 2021-10-22 2023-09-29 江苏瑞科生物技术股份有限公司 一种含有佐剂的新型冠状病毒免疫组合物及其应用
WO2023096990A1 (en) * 2021-11-24 2023-06-01 Flagship Pioneering Innovation Vi, Llc Coronavirus immunogen compositions and their uses
US12186387B2 (en) 2021-11-29 2025-01-07 BioNTech SE Coronavirus vaccine
KR20240125935A (ko) * 2021-11-30 2024-08-20 노바백스, 인코포레이티드 코로나바이러스 백신 제형물
CN114031675B (zh) * 2022-01-10 2022-06-07 广州市锐博生物科技有限公司 基于SARS-CoV-2的S蛋白的疫苗和组合物
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine
EP4709741A1 (en) * 2023-05-12 2026-03-18 Icosavax, Inc. Coronavirus spike glycoprotein receptor binding domains and uses thereof
US20250109187A1 (en) 2023-09-28 2025-04-03 Novavax, Inc. ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
ES2039229T3 (es) 1986-01-14 1993-09-16 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Procedimiento para la preparacion de complejos inmunogenicos y composiciones farmaceuticas que contienen estos complejos.
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
NL9002314A (nl) 1990-10-23 1992-05-18 Nederlanden Staat Immunogene complexen, in het bijzonder iscoms.
US6387373B1 (en) 1993-01-15 2002-05-14 Novavax, Inc. Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US6846489B1 (en) 1995-04-25 2005-01-25 Smithkline Beecham Biologicals S.A. Vaccines containing a saponin and a sterol
SE9600647D0 (sv) 1996-02-21 1996-02-21 Bror Morein Ny användning
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
CN102021147B (zh) 2003-03-24 2016-08-03 港大科桥有限公司 引起严重急性呼吸道综合征(sars)的新型人病毒及其应用
CN1237184C (zh) 2003-06-03 2006-01-18 中国科学院上海药物研究所 抗SARS－CoV药物作用靶标、药物筛选方法及抗SARS药物
EP1668112A4 (en) 2003-06-20 2009-04-29 Protein Sciences Corp SARS IMMUNOGENOUS EXPRESSING VECTORS, SUCH VECTORS OR EXPRESSION PRODUCTS COMPRISING THOSE COMPOSITIONS, PROCESSES AND TESTS FOR THE PREPARATION AND USE THEREOF
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
EP1508615A1 (en) * 2003-08-18 2005-02-23 Amsterdam Institute of Viral Genomics B.V. Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics
EP1882392A4 (en) 2005-05-10 2009-07-01 Monsanto Technology Llc GENES AND THEIR USES FOR PLANT IMPROVEMENTS
CN101939334B (zh) 2007-12-17 2015-01-14 医疗技术研究局 C型肝炎病毒抗体
ES2987238T3 (es) * 2008-12-09 2024-11-14 Novavax Inc Proteínas F del RSV modificadas y métodos de su uso
CN102470168A (zh) 2009-07-10 2012-05-23 伊斯克诺瓦公司 新组合物
RU2403063C1 (ru) 2009-08-28 2010-11-10 Автономная некоммерческая организация "Научно-исследовательский институт диагностики и профилактики болезней человека и животных" (АНО "НИИ ДПБ") Вакцина инактивированная комбинированная против вирусной диареи, рота-, коронавирусной болезней и эшерихиоза крупного рогатого скота
CA2805741C (en) 2010-07-23 2019-08-13 Karin Bengtsson Loevgren Composition including an iscom matrix and ectodomains
SG10201602434UA (en) * 2011-09-30 2016-05-30 Novavax Inc Recombinant nanoparticle rsv f vaccine for respiratory syncytial virus
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
EP2968510B1 (en) 2013-03-14 2019-10-09 President and Fellows of Harvard College Nanoparticle-based compositions
CN103554244B (zh) 2013-05-09 2016-09-07 香雪集团(香港)有限公司 具有抑制呼吸道病毒感染的活性的肽及其应用和制备方法
EP3046579A1 (en) * 2013-09-19 2016-07-27 Novavax, Inc. Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
WO2015080973A1 (en) 2013-11-26 2015-06-04 Baylor College Of Medicine A novel sars immunogenic composition
JP6975709B2 (ja) 2015-09-02 2021-12-01 ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. 安定化したウイルスクラスｉ融合タンパク質
CN114617959A (zh) * 2015-09-03 2022-06-14 诺瓦瓦克斯股份有限公司 具有改进的稳定性和免疫原性的疫苗组合物
WO2017161151A1 (en) * 2016-03-16 2017-09-21 Novavax, Inc. Vaccine compositions containing modified zika virus antigens
WO2018081318A1 (en) * 2016-10-25 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
WO2018170347A1 (en) 2017-03-17 2018-09-20 Modernatx, Inc. Zoonotic disease rna vaccines
WO2021147025A1 (en) 2020-01-22 2021-07-29 The University Of Hong Kong-Shenzhen Hospital Anti 2019-ncov vaccine
AU2021214064A1 (en) 2020-01-27 2022-08-18 Novavax, Inc. Coronavirus vaccine formulations
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2021154763A1 (en) 2020-01-28 2021-08-05 Modernatx, Inc. Coronavirus rna vaccines
TW202204380A (zh) 2020-01-31 2022-02-01 美商詹森藥物公司 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
CN111499692B (zh) * 2020-06-16 2020-12-04 国家纳米科学中心 靶向新型冠状病毒covid-19的多肽及其应用
US10906944B2 (en) 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines
US11149286B1 (en) 2020-08-17 2021-10-19 Mayo Foundation For Medical Education And Research Adenovirus vectors and methods for using adenovirus vectors
KR20230054719A (ko) 2020-08-24 2023-04-25 사노피 파스퇴르 인크 Sars-cov-2 감염에 대한 백신
EP4313143A4 (en) 2021-03-22 2025-06-18 Novavax, Inc. Coronavirus vaccine formulations
JP2024516309A (ja) 2021-05-05 2024-04-12 ノババックス，インコーポレイテッド コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法

Also Published As

Publication number Publication date
MX2022009167A (es) 2022-08-17
CN115720581A (zh) 2023-02-28
EP4097123A1 (en) 2022-12-07
EP4097123A4 (en) 2024-02-14
JP7792339B2 (ja) 2025-12-25
IL295142A (en) 2022-09-01
WO2021154812A8 (en) 2022-02-24
TW202142555A (zh) 2021-11-16
JP2023512648A (ja) 2023-03-28
KR20220141302A (ko) 2022-10-19
US20230070886A1 (en) 2023-03-09
WO2021154812A1 (en) 2021-08-05
US12691171B2 (en) 2026-07-28
AU2021214064A1 (en) 2022-08-18
GB202212336D0 (en) 2022-10-12
CA3165371A1 (en) 2021-08-05
GB2610070A (en) 2023-02-22
BR112022014830A2 (pt) 2022-09-27
JP2026026092A (ja) 2026-02-16

Similar Documents

Publication Publication Date Title
MX2022009167A (es) Formulaciones para vacuna contra coronavirus.
WO2023102448A3 (en) Coronavirus vaccine formulations
EP4494650A3 (en) Vaccine compositions having improved stability and immunogenicity
BR112023019301A2 (pt) Formulações de vacina de coronavírus
MY126588A (en) Intranasal influenza virus vaccine
NO20015073D0 (no) Vaksiner
WO2002028422A3 (en) Split enveloped virus preparation for intranasal delivery
WO2010019262A3 (en) Polyvalent vaccine
TW200722101A (en) Novel composition
WO2007024941A3 (en) Polyvalent vaccine
IN2014DN08830A (enExample)
WO2008148057A3 (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines
PH12022553462A1 (en) Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
HK1225631A1 (zh) 免疫原性中东呼吸综合征冠状病毒(mers-cov)组合物和方法
CY1112575T1 (el) Βελτιωμενα αδρανοποιημενα εμβολια fcv
MX2025012626A (es) Composiciones de vacuna sars-cov-2
PH12018500305B1 (en) Multivalent vlp conjugates
SG158154A1 (en) Methods to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
AU6721801A (en) The use of plant oil-bodies in vaccine delivery systems
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
MX2025009053A (es) Formulaciones de vacunas contra el vrs f
MY169061A (en) Modified marek's disease virus, and vaccines made therefrom
AR121151A1 (es) Formulaciones para vacuna contra coronavirus
AR127816A1 (es) Formulaciones de vacunas contra el coronavirus
HK1141793A (en) Cationic lipids compositions and methods for enhancing immune responses to vaccines